Quince Therapeutics, Inc. Cash Flow-to-Debt Ratio
Quince Therapeutics, Inc. cash flow-to-debt ratio. Quince Therapeutics, Inc. (QNCX) has a Cash Flow-to-Debt Ratio of -1.22x as of June 2026, meaning its operating cash flow of $-18.89 Million could theoretically repay -1% of its total liabilities ($15.51 Million) in one year. Check QNCX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Quince Therapeutics, Inc. (2017–2025)
Cash flow-to-debt ratio of Quince Therapeutics, Inc. from 2017 to 2025. Historical debt coverage capacity for Quince Therapeutics, Inc. across 9 annual periods. Also explore QNCX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Quince Therapeutics, Inc. Cash Flow-to-Debt Ratio by Year (2017–2025)
Quince Therapeutics, Inc. cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Quince Therapeutics, Inc.. For the full cash flow conversion analysis, see Quince Therapeutics, Inc. cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.32x | $-41.42 Million | $129.24 Million | ▲ +15.3% |
| 2024 | -0.38x | $-31.90 Million | $84.33 Million | ▼ -96.7% |
| 2023 | -0.19x | $-18.29 Million | $95.12 Million | ▲ +98.6% |
| 2022 | -13.28x | $-44.04 Million | $3.32 Million | ▼ -208.9% |
| 2021 | -4.30x | $-62.93 Million | $14.64 Million | ▼ -45.5% |
| 2020 | -2.95x | $-50.82 Million | $17.20 Million | ▲ +21.1% |
| 2019 | -3.74x | $-33.28 Million | $8.89 Million | ▲ +53.4% |
| 2018 | -8.03x | $-11.70 Million | $1.46 Million | ▼ -2186.9% |
| 2017 | -0.35x | $-9.83 Million | $28.00 Million | — |